close
Add to watchlist
Curis Inc (CRIS) Healthcare, Biotechnology & Drugs
Curis, Inc., a drug discovery and development company, focuses on the research and development of cancer therapeutics. The company, in collaboration with Genentech, is conducting a pivotal Phase II clinical trial on its lead molecule, GDC-0449 in advanced basal cell carcinoma patients, as well as various Phase II clinical trials in first-line metastatic colorectal cancer and in advanced ovarian cancer patients. It is also evaluating CUDC-101, a small molecule that is in a Phase I clinical testing and is designed to target histone deacetylase (HDAC), epidermal growth factor receptor (EGFR), and epidermal growth factor receptor 2 (Her2). In addition, Curis has a development candidate, CUDC-305, a Heat Shock Protein 90 (Hsp90) inhibitor. The company was founded in 2000 and is based in Cambridge, Massachusetts.
(login to add this stock to your watchlist or favorites)
Key Statistics
| Closing Price | 4.56 |
| Volume | 601408 |
| Volume Avg | 766634 |
| 52 Week High | 5.65 |
| 52 Week Low | 2.70 |
| PE | N/A |
| PE (group average) | 39 |
| EPS Year | -0.13 |
| EPS change Q/Q | -250% |
| EPS change Q/Q Yr ago | -75% |
| EPS change Q/Q next Q est | 0% |
| EPS change Y/Y | -200% |
| REV change Q/Q | -96.88% |
| REV change Q/Q Yr ago | -94.12% |
| EPS next Q est | -0.07 |
| EPS next Y est | -0.05 |
| Divident Annual | 0.00 |
| Dividend Yield | 0% |